Univdatos Whatsapp
Bronchitis Treatment Market

Bronchitis treatment Market is expected to foresee significant growth. APAC to lead the growth!

The bronchitis treatment market is expected to witness a CAGR of around ~5% during the forecast period (2021–2027). Bronchitis is when the tubes that carry air to your lungs, called the bronchial tubes, get inflamed and swollen. It can be described as either acute bronchitis or chronic bronchitis. This is caused mainly due to the sedentary lifestyle, addiction to cigarette smoke and chemical pollutants. Furthermore, rapid growth of the geriatric population and significant rise in respiratory disorders such as asthma, and lung cancer, among others is expected to drive the demand for effective bronchitis treatment. For instance, according to the World Population Ageing Report 2019 by United Nations (UN), In 2019, there were 703 million persons aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050.

For a detailed analysis of the Bronchitis treatment market browse throughhttps://univdatos.com/report/bronchitis-treatment-market/

Due to the COVID-19 pandemic, the industry has witnessed a strong upward hike in the growth of the market. This is mainly due to the increase in covid testing during the pandemic. Additionally, Bronchitis refers to inflammation of the main airways of the lungs so patients with bronchitis may be at risk of serious illness. In addition, both bronchitis and COVID-19 affect the lungs. As per the experts from The Johns Hopkins Organization, in COVID-19-related bronchitis is an issue of an excessive amount of sputum produced in the airways, resulting in coughing and chest congestion. The sputum also narrows the airways, making breathing more difficult. The Centers for Disease Control and Prevention (CDC) also informs that the coronavirus may cause more severe illness in those with bronchitis and lung diseases. These factors are the main reasons for the market growth during the forecast period. In addition,. Thus, the demand for Bronchitis treatment has increased phenomenally due to the COVID-19 pandemic.

Based on type, the market is classified into acute bronchitis and chronic bronchitis. Among them, in 2020, the acute category dominated the market and is expected to maintain its dominance throughout the forecast period. This is mainly due to the rising incidence of patients suffering from respiratory diseases, lung diseases, asthma, air pollution, and geriatric pollution. Additionally, the market growth is driven by the rapid growth of smoking, coupled with a rising geriatric population across the globe. In addition, breathing in air pollutants can irritate a patient’s airways and may cause shortness of breath, coughing, wheezing, asthma episodes, and chest pain. For instance, according to the world health organization (WHO), 9 out of 10 people breathe air containing high levels of pollutants. In 2019, 99% of the world population was living in places where the WHO air quality guidelines levels were not met. Both the number of cases and the prevalence of pollution have been steadily increasing over the past few decades.

For a detailed analysis of the Bronchitis treatment market browse throughhttps://univdatos.com/report/bronchitis-treatment-market/

Based on drug class, the market is bifurcated into antibiotics, anti-inflammatory, bronchodilators, and others. Among them, in 2020, the bronchodilator category held a significant share in the market. Bronchodilators are drugs often used as aerosols to widen the air passages by relaxing the bronchial muscle. They are effective in helping older, children and adults with asthma. Furthermore, asthmatic bronchitis is an inflammatory condition that causes airways to narrow. For instance, according to the world health organization (WHO), Asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths.

Based on distribution channel, the market is bifurcated into hospital hospitals pharmacies, retail pharmacies, and others. In 2020, the hospital pharmacies accounted for the majority share during the forecast period owing to the increasing construction of hospitals, the large number of patients treated at hospitals, the availability of trained professionals, and a surge in the number of respiratory cases, in the hospital setting. According to, institute for Health Metrics and Evaluation (IHME), Chronic respiratory diseases were responsible for 71·1 million YLLs and 32·4 million YLDs in 2019. Chronic obstructive pulmonary disease (COPD) and asthma were the two largest contributors to the global respiratory disease burden.

Request for a Sample of the report browse through – https://univdatos.com/get-a-free-sample-form-php/?product_id=21544

For a better understanding of the market adoption of the Bronchitis treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Rest of Asia-Pacific); and the Rest of World. In 2020. North America held an extensive market share owing to the rising prevalence of bronchitis, awareness, and well-established medical infrastructure and facilities. In addition, the APAC region has the fastest growth during the forecast period. This is mainly due to the increasing environmental pollution, rising geriatric population with various respiratory diseases, and growing prevalence of lung diseases.

Some of the major players operating in the market include AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy’s Laboratories Ltd, Sanofi SA, Boehringer Ingelheim International GmbH, Pfizer Inc., Melinta Therapeutics, Lupin Limited, Cadila Healthcare Limited.

Bronchitis treatment Market Segmentation

Market Insight, by Type

  • Acute Bronchitis
  • Chronic Bronchitis

Market Insight, by Drug Class

  • Antibiotics
  • Anti-inflammatory Drugs
  • Bronchodilator
  • Other Drugs

Market Insight, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Market Insight, by Region

  • North America
    • U.S.
    • Canada
    • Rest of North America
    • Europe
      • Germany
      • United Kingdom
      • France
      • Spain
      • Italy
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Rest of Asia-Pacific
    • Rest of World

Top Company Profiles

  • AstraZeneca PLC
  • Novartis AG
  • GlaxoSmithKline PLC
  • Dr. Reddy’s Laboratories Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Melinta Therapeutics
  • Lupin Limited
  • Cadila Healthcare Limited

Leave A Comment

Select Language